Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)

Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)

The objective of CISCO is therefore to identify prognostic biomarkers of MS activity in early-stage patients.

Patients :

Inclusion Criteria:

• Patients with clinically isolated syndrome (CIS) participating in the OFSEP cohort (French MS Observatory)
• At least 18 years of age
• Diagnosed with MS according to criteria 2017 at the time of their last visit.
• Non-opposition to participation in the study
• Having had at least one visit in the year following collection
• Follow-up for at least 1 year after collection.
• Having signed the OFSEP consent

Exclusion Criteria:

• CIS patients with progressive MS

Healthy volunteers :

Inclusion Criteria:

• Age 18 years or older
• Having participated in the ABCD-SEP clinical trial promoted by the Rennes University Hospital (NCT03744351).
• Matched on age and sex to patients of interest in the OFSEP cohort
• Not having objected to participation in the study

Exclusion Criteria:

• Persons of full age subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty